# First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis

> **NCT01674309** · PHASE2 · COMPLETED · sponsor: **Federation Francophone de Cancerologie Digestive** · enrollment: 65 (actual)

## Conditions studied

- Adenocarcinoma of Rectum

## Interventions

- **DRUG:** FOLFORINOX

## Key facts

- **NCT ID:** NCT01674309
- **Lead sponsor:** Federation Francophone de Cancerologie Digestive
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2016-01
- **Final completion:** 2016-10
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2020-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01674309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01674309, "First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01674309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*